A 52-WEEK MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF REMIBRUTINIB IN ADULT PARTICIPANTS WITH SEVERE CHRONIC PRURITUS OF UNKNOWN ORIGIN (CPUO)

Registry ID

CLOU064R12302

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

NOVARTIS PHARMACEUTICALS CANADA INC

Last update

2026-07-09

Conditions

• PRURITIS

Related clinical trials

• AN EXPLORATORY PROOF OF CONCEPT STUDY TO ASSESS THE PHARMACOKINETICS/PHARMACODYNAMICS OF NEMOLIZUMAB (CD14152) IN ADULT PARTICIPANTS WITH CHRONIC PRURITUS OF UNKNOWN ORIGIN (CPUO)
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB FOR THE TREATMENT OF PRURITUS OF LICHEN SIMPLEX CHRONICUS (LSC) IN ADULTS
• ¿MASTER PROTOCOL OF TWO RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, PARALLEL GROUP STUDIES TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH CHRONIC PRURITUS OF UNKNOWN ORIGIN (CPUO)¿
• LONG-TERM SAFETY AND TOLERABILITY STUDY OF LINERIXIBAT FOR THE TREATMENT OF CHOLESTATIC PRURITUS IN PARTICIPANTS WITH PRIMARY BILIARY CHOLANGITIS.

View on source registry